Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. - Test2 - elhamkhani - TriplyDB

Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.

Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.

http://www.wikidata.org/entity/Q38168996

about

Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population Diagnostic approach to eosinophilic renal neoplasms Xp11.2 translocation renal cell carcinomas in young adults Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.Partial nephrectomy for the treatment of translocation renal cell carcinoma.RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.Fine-needle aspiration findings of Xp11 translocation renal cell carcinoma metastatic to a hilar lymph node.A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesis TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features.PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq.Clinicopathological characteristics of Xp11.2 translocation renal cell carcinoma in adolescents and adults: Diagnosis using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis.MicroRNA expression profiling of Xp11 renal cell carcinoma.Soft tissue sarcomas: From a morphological to a molecular biological approach.Does the Fuhrman or World Health Organization/International Society of Urological Pathology Grading System Apply to the Xp11.2 Translocation Renal Cell Carcinoma?: A 10-Year Single-Center Study.[The translocation carcinoma: A pediatric renal tumor also in adults].Unsuspected Xp11 Translocation Renal Neoplasm Associated With Contralateral Clear Cell Carcinoma.Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.

P2860

Q31046172-A55BA71F-5F32-4943-9ED7-79FBB4B5A8D0 Q35155653-6401BB35-4D14-4818-9A49-7A108BCF742E Q35678902-6D9C3AC2-C9DE-4D54-B514-CAE9BDA3751C Q36001179-BEDC853F-1E87-4580-BF87-1D21128135B8 Q36151526-913E62F4-63F4-471C-8E0E-5047ADC444C1 Q36205571-CABBFDBC-065B-460B-B8D6-67AFA2290E94 Q36288139-180640A6-2CBF-4C53-A38A-AE37A1DE0892 Q38375566-001A9332-831A-4A3A-BC83-7619A56FF5BF Q39010157-091DF13E-9328-4039-9623-9722E0F32231 Q39129490-6F6A0ACE-A216-4D30-95E4-040CC2D7A7CA Q39416850-F36BC400-BF3E-473B-B354-0B7071D9B72D Q39922019-65B281B7-FF53-4ACB-A137-D63DB45C2500 Q41670942-F2AFFBAE-A7B2-4589-92C1-09AEB722402D Q42364326-5A85AD76-C230-4A5D-AA72-51A7747970F1 Q42773286-B87907A4-3069-4F1E-BFCF-739276278ABC Q42776882-8621BEF2-645E-498B-A7B7-3101F17A9006 Q47965589-2B5CC139-D1CE-41A1-9966-9DDBAF38811F Q50726690-02779948-3968-41EB-AC71-D93E919E2E81 Q51817033-9E3E18DC-9B13-48B3-A799-BF6361131453 Q52640027-46384B3C-F24E-4512-B0D1-C410F72750B5 Q53149212-651BD8E3-1773-440A-9A5B-59FDC735EC9A Q53220937-C5CB1D12-BC8F-421B-8F23-AE2CD0626622 Q55315179-3717C468-E58B-4509-AE18-812147C39BF6

P2860

Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.

http://www.wikidata.org/entity/Q38168996

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Clinical heterogeneity of Xp11 ...... usion subtype, age, and stage.

@en

type

label

Clinical heterogeneity of Xp11 ...... usion subtype, age, and stage.

@en

prefLabel

Clinical heterogeneity of Xp11 ...... usion subtype, age, and stage.

@en

P1433

Q38168996-E18F36A1-62BE-4883-8579-3477A5A89285

P1476

Q38168996-96B2F789-C988-488C-90D1-64C23A0DFBE0

P2093

Q38168996-3B585556-DDC6-4D14-B236-F4BAEB305677

Q38168996-66900E29-D009-4107-8C35-C84259286CAB

Q38168996-6CDA961D-7B9E-4D60-979F-EB4FC9F4F8F6

Q38168996-89956DD9-EEFF-4487-A278-5264D2659EE7

Q38168996-96F00997-240A-4D38-AD64-34786E9C47FA

Q38168996-BEB28916-E625-4246-9C62-676D3AFCA4DB

Q38168996-CE874B78-832F-4647-8421-D9E145696755

Q38168996-D18584C9-E2FB-4B49-A2D0-E35F9889A075

P2860

Q38168996-023A1920-E8EE-4EA8-BABF-1413FCF8A72B

Q38168996-036CFEAF-F0FF-4884-A0C0-D4DFA748F93E

Q38168996-04786280-9655-4EE2-82C7-7B2FBD6A1866

Q38168996-12E56368-2A8C-4021-80DE-CD592DA8A73D

Q38168996-319E6603-B933-480B-AE91-7E55499A45B9

Q38168996-34CC8E14-7258-4FEF-B7F2-00F704185134

Q38168996-3853FB1A-420E-49E1-9F93-7C951362090C

Q38168996-398D0D05-E7B9-4998-AF49-A37A1DC1A05E

Q38168996-43E957D0-A3CD-422B-8E54-EEE98317F19A

Q38168996-4D98559F-EF76-459C-A9D2-63BB2305D27D

P2888

Q38168996-3A236691-BBCA-4E7C-893E-A199C1181853

P304

Q38168996-4EC145B5-E95C-4181-BACB-44A4B4496382

P31

Q38168996-0B0D488F-1A1D-4939-BE0D-F81868CD86E4

P356

Q38168996-2B7E5B4D-B2DC-4A44-8111-5558B477B3A8

P433

Q38168996-8C493C37-8410-40D6-A6C3-FA0FC88D5966

P478

Q38168996-01DD6C7F-52FF-498E-8EA0-B68946B07B6A

P50

Q38168996-CA86A91B-984A-42F5-80F8-4F272AC52BE7

P577

Q38168996-8C456A5F-3477-45DF-92AF-21A481510F3A

P6179

Q38168996-BF1E8289-9D90-4E43-A14B-678B56633D8A

P698

Q38168996-3E9A71AE-1B86-47C5-9308-8EC23DC0060C

P356

MODPATHOL.2013.208

P1433

Modern Pathology

P1476

Clinical heterogeneity of Xp11 ...... usion subtype, age, and stage.

@en

P2093

Andrea P Subhawong

http://www.w3.org/2001/XMLSchema#string

Carla L Ellis

http://www.w3.org/2001/XMLSchema#string

George J Netto

http://www.w3.org/2001/XMLSchema#string

Guido Martignoni

http://www.w3.org/2001/XMLSchema#string

John N Eble

http://www.w3.org/2001/XMLSchema#string

Jonathan I Epstein

http://www.w3.org/2001/XMLSchema#string

Minghao Zhong

http://www.w3.org/2001/XMLSchema#string

Pedram Argani

http://www.w3.org/2001/XMLSchema#string

P2860

Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents

The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene

Molecular cytogenetics of t(X;1)(p11.2;q21) with complex rearrangements in a renal cell carcinoma.

Two new cases of papillary renal cell carcinoma with t(X;1)(p11;q21) in females.

Translocation (X;1) associated with a nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype.

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group

XP11.2 translocation renal cell carcinoma: clinical experience of Taipei Veterans General Hospital.

Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype.

Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis.

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

P2888

modpathol.2013.208

P304

875-886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2013.208

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047371257

http://www.w3.org/2001/XMLSchema#string

P698

24309327

http://www.w3.org/2001/XMLSchema#string